These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 12731088)

  • 1. Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
    McVie-Wylie AJ; Ding EY; Lawson T; Serra D; Migone FK; Pressley D; Mizutani M; Kikuchi T; Chen YT; Amalfitano A
    J Gene Med; 2003 May; 5(5):399-406. PubMed ID: 12731088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY; Ho CH; Hsieh YH; Kikuchi T
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice.
    Ding EY; Hodges BL; Hu H; McVie-Wylie AJ; Serra D; Migone FK; Pressley D; Chen YT; Amalfitano A
    Hum Gene Ther; 2001 May; 12(8):955-65. PubMed ID: 11387060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
    Kiang A; Hartman ZC; Liao S; Xu F; Serra D; Palmer DJ; Ng P; Amalfitano A
    Mol Ther; 2006 Jan; 13(1):127-34. PubMed ID: 16169280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency.
    Tsujino S; Kinoshita N; Tashiro T; Ikeda K; Ichihara N; Kikuchi H; Hagiwara Y; Mizutani M; Kikuchi T; Sakuragawa N
    Hum Gene Ther; 1998 Jul; 9(11):1609-16. PubMed ID: 9694159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
    Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.
    Kyosen SO; Iizuka S; Kobayashi H; Kimura T; Fukuda T; Shen J; Shimada Y; Ida H; Eto Y; Ohashi T
    Gene Ther; 2010 Apr; 17(4):521-30. PubMed ID: 20033064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
    Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
    J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector.
    Sun BD; Chen YT; Bird A; Amalfitano A; Koeberl DD
    Mol Ther; 2003 Feb; 7(2):193-201. PubMed ID: 12597907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction.
    Ding E; Hu H; Hodges BL; Migone F; Serra D; Xu F; Chen YT; Amalfitano A
    Mol Ther; 2002 Apr; 5(4):436-46. PubMed ID: 11945071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
    Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
    Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.
    Amalfitano A; McVie-Wylie AJ; Hu H; Dawson TL; Raben N; Plotz P; Chen YT
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8861-6. PubMed ID: 10430861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.